Remdesivir nanosuspension for potential nasal drug delivery: determination of pro-inflammatory interleukin IL-4 mRNA expression and industrial scale-up strategy
Source abstract
Abstract
Remdesivir is among theSARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) drugs with great potential. However, its poor aqueous solubility restricts its therapeutic action. Therefore, the aim was to develop the nasal delivery of Remdesivir with solubilizing polymers, poloxamer 407, and β-cyclodextrin, which resulted in significant solubility enhancement. In addition, this nanosuspension was developed for the first time for pulmonary delivery to enhance the in vivo performance of remdesivir. Remdesivir solubility and biocompatibility were greatly improved by polymeric encapsulation at the nanoscale. The nanosuspension was prepared by the modified precipitation-ultra sonication process and showed a good particle size 500 nm ± 20 nm, with polydispersity (0.226 ± 0.02) and zeta potential (-16.0 ± 2 mV). The nasal formulation was also assessed for in vitro dissolution and diffusion, in addition to toxicity investigations (Hemolysis, MTT assay). The conversion of remdesivir crystals to an amorphous form was verified by characterization studies (XRD and DSC). The morphology of the nano particles was determined by SEM method and found to be spherical and of uniform shape. FTIR study was performed to determine the drug compatibility with the polymers and was satisfactory. Histopathology study on goat nasal mucosa showed no adverse effects of the formulation on nasal tissues. Analysis using reverse transcription polymerase chain reaction revealed noticeably reduced levels of IL-4 mRNA expression (pro-inflammatory cytokines). In comparison to intravenous delivery, nasal delivery of remdesivir nanosuspension is patient-complaint and easy to use. The outcomes of this study demonstrate the potential for delivering remdesivir nanosuspension via the nasal route.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Inhalation and Respiratory Drug Delivery · Drug-Induced Adverse Reactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395(10236):1569–157810.1016/S0140-6736(20)31022-9 ↗
2. Wang Y, Zhou F, Zhang D, Zhao J, Du R, Hu Y, Cheng Z, Gao L, Jin Y, Luo G, Fu S, Lu Q, Du G, Wang K, Lu Y, Fan G, Zhang Y, Liu Y, Ruan S, Liu W, Jaki T, Hayden FG, Horby PW, Cao B, Wang C (2020) Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials 21(1):42210.1186/s13063-020-04352-9 ↗
3. Konkolova E, Dejmek M, Hřebabecký H, Šála M, Böserle J, Nencka R, Boura E (2020) Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Res 182:10489910.1016/j.antiviral.2020.104899 ↗
4. Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J, Farnung L, Siewert A, Höbartner C, Cramer P (2021) Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun 12(1):27910.1038/s41467-020-20542-0 ↗
5. Uddin M, MustafaF, Rizvi TA, Loney T, Suwaidi HA, Al-Marzouqi AHH, Eldin AK, Alsabeeha N, Adrian TE, Stefanini C, Nowotny N, Alsheikh-Ali A, Senok AC (2020) SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions. Viruses 12(5):526. https://doi.org/10.3390/v1205052610.3390/v12050526 ↗
6. Maus A, Strait L, Zhu D (2021) Nanoparticles as delivery vehicles for antiviral therapeutic drugs. Eng Regen 2:31–46
7. Gurunathan S, Qasim M, Choi Y, Do JT, Park C, Hong K, Kim JH, Song H (2020) Antiviral potential of nanoparticles-can nanoparticles fight against coronaviruses? Nanomaterials (Basel) 10(9):1645. https://doi.org/10.3390/nano1009164510.3390/nano10091645 ↗
8. Lamb YN (2020) Remdesivir: first approval. Drugs 80(13):1355–136310.1007/s40265-020-01378-w ↗
9. Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastri E, D’Avolio A, Ippolito G, Agrati C (2020) Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75(10):2977–298010.1093/jac/dkaa239 ↗
10. Cao Y-C, Deng Q-X, Dai S-X (2020) Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis 35:10164710.1016/j.tmaid.2020.101647 ↗
11. Kazi M et al (2023) Oral bioactive self-nanoemulsifying drug delivery systems of remdesivir and baricitinib: a paradigmatic case of drug repositioning for cancer management. Molecules 28(5):223710.3390/molecules28052237 ↗
12. Tran P et al (2019) Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics 11(3):13210.3390/pharmaceutics11030132 ↗
13. Haimhoffer Á et al (2019) Cyclodextrins in drug delivery systems and their effects on biological barriers. Sci Pharm 87(4):3310.3390/scipharm87040033 ↗
14. Ahlawat J, Henriquez G, Narayan M (2018) Enhancing the delivery of chemotherapeutics: role of biodegradable polymeric nanoparticles. Molecules 23(9):215710.3390/molecules23092157 ↗
15. Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13(3–4):144–15110.1016/j.drudis.2007.10.021 ↗
16. Wilczewska AZ et al (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64(5):1020–103710.1016/S1734-1140(12)70901-5 ↗
17. Arshad MS et al (2021) A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing. Adv Drug Deliv Rev 178:11384010.1016/j.addr.2021.113840 ↗
18. Zafar A (2020) Development of oral lipid based nano-formulation of dapagliflozin: optimization, in vitro characterization and ex vivo intestinal permeation study. J Oleo Sci 69(11):1389–140110.5650/jos.ess20162 ↗
19. Zafar A, Alruwaili NK, Imam SS, Alsaidan OA, Alharbi KS, Alzarea SI, Yasir M, Afzal M, Alshehri S, Alanazi AS (2023) Bioactive luteolin entrapped chitosan-plga nanoparticles: formulation optimization to in-vivo preclinical evaluation. J Clust Sci 34(1):437–44910.1007/s10876-022-02232-7 ↗
20. Khan N et al (2020) Improvement of ocular efficacy of levofloxacin by bioadhesive chitosan coated PLGA nanoparticles: Box-Behnken design, in-vitro characterization, antibacterial evaluation and scintigraphy study. Iran J Pharm Res: IJPR 19(1):292
21. Zafar A et al (2022) Formulation of self-nanoemulsifying drug delivery system of cephalexin: physiochemical characterization and antibacterial evaluation. Polymers 14(5):105510.3390/polym14051055 ↗
22. Rezagholizadeh A et al (2021) Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol 897:17392610.1016/j.ejphar.2021.173926 ↗
23. Moccia M et al (2015) How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opin Drug Deliv 12(12):1829–183510.1517/17425247.2015.1078789 ↗
24. Hu K et al (2019) Authentication of Eucommia ulmoides seed oil using Fourier transform infrared and synchronous fluorescence spectroscopy combined with chemometrics. J Oleo Sci 68(11):1073–108410.5650/jos.ess19160 ↗
25. Yang D (2021) Application of nanotechnology in the COVID-19 pandemic. Int J Nanomed 16:62310.2147/IJN.S296383 ↗
26. Fadeel B, Kostarelos K (2020) Grouping all carbon nanotubes into a single substance category is scientifically unjustified. Nat Nanotechnol 15(3):164–16410.1038/s41565-020-0654-0 ↗
27. Taher M, Shaari SS, Susanti D (2021) Potential nanospray inhalation of remdesivir and hydroxychloroquine using poly (lactic-co-glycolic) acid as fast delivery for COVID-19 treatment. J Pharm 1(1):34–4410.31436/jop.v1i1.50 ↗
28. Vartak R et al (2021) Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine 16(14):1187–120210.2217/nnm-2020-0475 ↗
29. Halevas E et al (2022) Remdesivir-loaded bis-MPA hyperbranched dendritic nanocarriers for pulmonary delivery. J Drug Deliv Sci Technol 75:10362510.1016/j.jddst.2022.103625 ↗
30. Saindane NS, Pagar KP, Vavia PR (2013) Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. AAPS PharmSciTech 14(1):189–19910.1208/s12249-012-9896-y ↗
31. Bulduk I, Akbel E (2021) A comparative study of HPLC and UV spectrophotometric methods for remdesivir quantification in pharmaceutical formulations. J Taibah Univ Sci 15(1):507–51310.1080/16583655.2021.1991737 ↗
32. Mehmood Y et al (2022) Developing of SiO2 nanoshells loaded with fluticasone propionate for potential nasal drug delivery: determination of pro-inflammatory cytokines through mRNA expression. J Funct Biomaterials 13(4):22910.3390/jfb13040229 ↗
33. Mehmood Y et al (2020) In-vitro and in-vivo evaluation of velpatasvir-loaded mesoporous silica scaffolds. A prospective carrier for drug bioavailability enhancement. Pharmaceutics 12(4):30710.3390/pharmaceutics12040307 ↗
34. Mehmood Y et al (2023) Designing of SiO2 mesoporous-nanoparticles loaded with mometasone furoate for potential nasal drug delivery: ex vivo evaluation and determination of pro-inflammatory interferon and interleukins mRNA expression. Front Cell Dev Biol 10:241110.3389/fcell.2022.1026477 ↗
35. Mehmood Y, Youusaf H, Farooq U, Riaz H, Saleem N, Hassan M, Mahmood RK, Raheemmalik A, Ashaq M, Kashif A, Zahra T, Raza SA (2019) Formulation development using different natural and semi synthetic polymers, in vitro evaluation of colon targeted Sulfasalazine tablets for ulcerative colitis. Int J Biosci 15(1):42–55. https://doi.org/10.12692/ijb/15.1.42-5510.12692/ijb/15.1.42-55 ↗
36. Zhang Y et al (2010) DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 12(3):263–27110.1208/s12248-010-9185-1 ↗
37. Barkat K et al (2018) Development and characterization of pH-responsive polyethylene glycol-co-poly (methacrylic acid) polymeric network system for colon target delivery of oxaliplatin: its acute oral toxicity study. Adv Polym Technol 37(6):1806–182210.1002/adv.21840 ↗
38. Khalid I et al (2018) Preparation and characterization of alginate-PVA-based semi-IPN: controlled release pH-responsive composites. Polym Bull 75(3):1075–109910.1007/s00289-017-2079-y ↗
39. Aslantürk, Ö. (2018). In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages.
40. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–6310.1016/0022-1759(83)90303-4 ↗
41. Patel S et al (2009) In-vitro cytotoxicity activity of Solanum nigrum extract against Hela cell line and Vero cell line. Int J Pharm Pharm Sci 1(1):38–46
42. Mehmood Y et al (2019) Facile synthesis of mesoporous silica nanoparticles using modified solgel method: optimization and in vitro cytotoxicity studies. Pak J Pharm Sci 32(4):1805–1812
43. Shahid H et al (2019) Immunomodulatory and anti-inflammatory potential of curcumin for the treatment of allergic asthma: effects on expression levels of pro-inflammatory cytokines and aquaporins. Inflammation 42(6):2037–204710.1007/s10753-019-01066-2 ↗
44. Baek JH, Lee S-Y, Oh S-W (2021) Enhancing safety and quality of shrimp by nanoparticles of sodium alginate-based edible coating containing grapefruit seed extract. Int J Biol Macromol 189:84–9010.1016/j.ijbiomac.2021.08.118 ↗
45. Thakur S et al (2020) Thermosensitive injectable hydrogel containing carboplatin loaded nanoparticles: a dual approach for sustained and localized delivery with improved safety and therapeutic efficacy. J Drug Deliv Sci Technol 58:10181710.1016/j.jddst.2020.101817 ↗
46. Abdul AH et al (2020) Equator assessment of nanoparticles using the Design-Expert software. Int J Pharm Sci Nanotechnol 13(1):4766–4772
47. Jacob S, Nair AB, Shah J (2020) Emerging role of nanosuspensions in drug delivery systems. Biomaterials Res 24(1):1–1610.1186/s40824-020-0184-8 ↗
48. Singare DS et al (2010) Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm 402(1–2):213–22010.1016/j.ijpharm.2010.09.041 ↗
49. Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. Pharm Ther 42(12):742
50. Priyono SR, Rahmasari R (2022) Preparation, cellular uptake, and cytotoxic evaluation of remdesivir-hydroxypropyl-β-cyclodextrin inclusion complex. Biomed Pharmacol J 15(2):717–72710.13005/bpj/2410 ↗
51. Menezes P et al (2014) Inclusion complex of (−)-linalool and β-cyclodextrin. J Therm Anal Calorim 115(3):2429–243710.1007/s10973-013-3367-x ↗
52. Tiwari A et al (2016) Microsponge: an augmented drug delivery system. Am J PharmTech Res 6(6):79–95
53. Várnai B et al (2022) Molecular interactions in remdesivir-cyclodextrin systems. J Pharm Biomed Anal 209:11448210.1016/j.jpba.2021.114482 ↗
54. Adriaensen G, Lim KH, Fokkens WJ (2017) Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. Int Forum Allergy Rhinol 7(8):813–82010.1002/alr.21963 ↗
55. Ballal N et al (2009) Susceptibility of Candida albicans and Enterococcus faecalis to chitosan, chlorhexidine gluconate and their combination in vitro. Aust Endod J 35(1):29–3310.1111/j.1747-4477.2008.00126.x ↗